Recombinant canarypox virus vaccine co-expressing ...
Description
Citation
| Title | Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep |
| Author(s) | J. Boone, U. Balasuriya, K. Karaca, Jean-Christophe Audonnet, J. Yao, L. He, R. Nordgren, F. Monaco, G. Savini, I. Gardner, N. James MacLachlan |
| Journal | Vaccine |
| Volume | 25 |
| Issue | |
| Start page | 672 |
| End page | 678 |
| Abstract | We describe the development and preliminary characterization of a recombinant canarypox virus vectored vaccine for protective immunization of ruminants against bluetongue virus (BTV) infection. Sheep (n=6) immunized with recombinant canarypox virus vector (BTV-CP) co-expressing synthetic genes encoding the two outer capsid proteins (VP2 and VP5) of BTV serotype 17 (BTV-17) developed high titers (40–160) of virus-specific neutralizing antibodies and were resistant to challenge with a field strain of BTV-17. In contrast, sheep (n=5) immunized with a commercial recombinant canarypox virus vector expressing the E and preM genes of West Nile virus were seronegative to BTV and developed pyrexia, lymphopenia, and extended, high-titered viremias following challenge exposure to the field strain of BTV-17. These data confirm that the BTV-CP vaccine may be useful for the protective immunization of ruminants against bluetongue, and it may avoid the problems inherent to live-attenuated (LA) BTV vaccines. |
| DOI | 10.1016/j.vaccine.2006.08.025 |
| ISSN | 0264-410X |
Using APA 6th Edition citation style.
[Page generation failure. The bibliography processor requires a browser with Javascript enabled.]
Times viewed: 45
